Thyroid
Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism

Investigators:

Tim Cheetham tim.cheetham@nuth.nhs.uk

Lay summary:

There is a pressing need to develop better treatments for young people with Graves’ disease. There have been no new treatment options for young people with Graves’ hyperthyroidism for over 60 years. Current treatments are disappointing because they do not usually result in a cure and require the young person to take medication for life. For most young people Graves’ hyperthyroidism will be a chronic condition with a substantial impact on long term well-being. This MRC-funded trial, conducted by a team based at Newcastle University, is looking to see whether a single dose of the drug rituximab can improve the cure rate in young people with Graves’ hyperthyroidism when administered with a short course of conventional therapy (the drug carbimazole). This trial is a novel approach towards the management of a condition that is currently extremely frustrating for the young person and their family.

Start Date: 01/11/2016
End Date: 31/10/2018

Further Information: